Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited
Company type	Listed Public Company
Traded as	ASX: BOT
Industry	Biotechnology
Headquarters	Perth, Western Australia, and Philadelphia, USA
Area served	Global
Key people	Vince Ippolito, President and executive chairman; Matt Callahan, Founder and executive director; Dr Stewart Washer, Director; Dr Bill Bosch, Chief scientific officer and executive director; Danny Sharp, Non-executive director;
Products	BTX 1503 \| For the treatment of moderate to severe acne BTX 1702 \| For the treatment of rosacea BTX 1204A \| For the treatment of moderate atopic dermatitis BTX 1801 \| For use in a variety of antimicrobial applications
Website	www.botanixpharma.com

Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic^[1] cannabinoid^[2] company, focusing on the compound Cannabidiol.^[3] The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex,^[4] for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.